Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

DexCom nets $50.6mm with its IPO

Executive Summary

Medical device company DexCom (glucose monitors) has netted $50.6mm with its initial public offering of 4.7mm common shares. The company priced the shares at $12 each, the low end of its original range, which was $12-14 when it filed in February (just a month after grossing $22.5mm with its Series D round).
Deal Industry
  • Medical Devices
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Implantable Devices
    • Monitoring Equipment & Devices
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies